Last reviewed · How we verify
NCT02350868
Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment
Phase 1 trial testing MPT0E028 in Advanced Solid Malignancies in 23 participants. Completed in 19 January 2019.
19 January 2019
Quick facts
| Lead sponsor | Taipei Medical University |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 23 |
| Start date | 24 April 2015 |
| Primary completion | 19 January 2019 |
| Estimated completion | 19 January 2019 |
| Sites | 2 locations across Taiwan |
Drugs / interventions tested
- MPT0E028 — full drug profile →
Conditions studied
- Advanced Solid Malignancies — all drugs for Advanced Solid Malignancies →
Sponsor
Taipei Medical University
Who can join
20 and older, any sex, with Advanced Solid Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Dose Escalation Phase will determine the MTD of MPT0E028 and evaluate its safety and tolerability, PK, PD, and preliminary clinical effects; the subsequent Dose Confirmation Phase will be a cohort expansion at or below the MTD (i.e., an RP2D) of MPT0E028.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy.
Yang Y, Zhang M, Wang Y. · · 2022 · cited 96× · PMID 39036551 · DOI 10.1016/j.jncc.2022.09.002 -
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy.
Banik D, Moufarrij S, Villagra A. · · 2019 · cited 96× · PMID 31067680 · DOI 10.3390/ijms20092241 -
Targeting the epigenome in in-stent restenosis: from mechanisms to therapy.
Yang X, Yang Y, Guo J, Meng Y, et al · · 2021 · cited 47× · PMID 33664994 · DOI 10.1016/j.omtn.2021.01.024 -
Pharmacological targeting of the cancer epigenome.
Mabe NW, Perry JA, Malone CF, Stegmaier K. · · 2024 · cited 36× · PMID 38937652 · DOI 10.1038/s43018-024-00777-2 -
Histones and heart failure in diabetes.
Yerra VG, Advani A. · · 2018 · cited 25× · PMID 29934664 · DOI 10.1007/s00018-018-2857-1 -
Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
Chao MW, Chang LH, Tu HJ, Chang CD, et al · · 2019 · cited 24× · PMID 31142371 · DOI 10.1186/s13148-019-0681-6 -
Processes and therapeutic perspectives of acylation modifications of lysine and cysteine in tumors.
Jiang J, Chen J, Huang S, Tian Y, et al · · 2026 · PMID 41630001 · DOI 10.1186/s12964-026-02707-4 -
Next-Generation HDAC Inhibitors: Advancing Zinc-Binding Group Design for Enhanced Cancer Therapy.
Hawash M. · · 2025 · PMID 41440016 · DOI 10.3390/cells14241997
Verify or expand the search:
- PubMed search for NCT02350868
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Solid Malignancies
Currently open trials in the same condition.
- NCT07223047 — A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agent · Phase 1, PHASE2 · recruiting
- NCT06927297 — Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors · Phase 1 · recruiting
- NCT06760481 — Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIG · Phase 1 · active not recruiting
- NCT06899061 — Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saru · Phase 1 · active not recruiting
- NCT05417594 — Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignanc · Phase 1, PHASE2 · recruiting
Other Taipei Medical University trials
Trials by the same sponsor.
- NCT07496658 — Nutritional Status, Nutritional Knowledge and Mental Health Among Indonesian Migrant Workers in Taiwan · not yet recruiting
- NCT06930313 — Compassion-Based Intervention for Lung Cancer Caregivers (CBI-LCC) · NA · not yet recruiting
- NCT07349446 — Effects of Circadian-Based Acupressure on Sleep Quality in Nursing Home Residents · NA · not yet recruiting
- NCT07259369 — The Effects of an App-based Acupressure on Alleviating Fatigue, Pruritus, and Sleep Quality Among Hemodialysis Patients · NA · not yet recruiting
- NCT07275372 — Using Virtual Humans to Teach Cognitive Function Assessment to Nursing Students · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02350868 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taipei Medical University
- Last refreshed: 11 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02350868.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing